Introduction: The Hidden Genetic Architecture of Diabetic Foot Ulcers

Diabetic foot ulcers (DFUs) represent one of the most serious and costly complications of diabetes mellitus, affecting an estimated 15-25% of all diabetic patients during their lifetime. These chronic wounds, once established, carry a grim trajectory: they are the leading cause of non-traumatic lower extremity amputations worldwide, with five-year mortality rates rivaling many aggressive cancers. While clinical guidelines have long emphasized the triad of peripheral neuropathy, peripheral arterial disease, and glycemic control as primary drivers of ulcer formation, a growing body of evidence points to an often-overlooked contributor: the patient's genetic makeup. Understanding the genetic factors that govern susceptibility to diabetic foot ulcers is not merely an academic exercise — it represents a paradigm shift toward risk stratification, personalized prevention, and ultimately, a reduction in the human and economic toll of this devastating condition.

The clinical challenge is well recognized. Two patients with identical HbA1c levels, similar durations of diabetes, and comparable neuropathic symptoms can follow completely divergent paths: one remains ulcer-free for decades while the other develops recalcitrant wounds within years of diagnosis. This variability cannot be explained solely by behavioral or environmental factors. Instead, it suggests that inherited genetic variants modulate an individual's wound healing capacity, vascular responsiveness, inflammatory signaling, and tissue resilience. Recent advances in genomics, including genome-wide association studies (GWAS) and candidate gene analyses, have begun to identify specific alleles that increase or decrease DFU risk. This article synthesizes the current understanding of these genetic factors, examines their mechanistic underpinnings, and explores how this knowledge is being translated into clinical tools for risk assessment and targeted therapy.

Importantly, the genetic story of DFU susceptibility is not a simple monogenic narrative. It is polygenic, pleiotropic, and deeply interconnected with epigenetic modifications triggered by the diabetic milieu. The interplay between inherited variants and acquired metabolic derangements creates a complex risk landscape. By parsing this landscape, clinicians and researchers can identify patients who warrant more aggressive surveillance, test novel therapeutic strategies that address underlying biological vulnerabilities, and move beyond the one-size-fits-all approach that has characterized diabetic foot care for decades.

A 2023 systematic review in Diabetologia demonstrated that family history of DFU independently increases ulcer risk by approximately 1.8-fold after controlling for classic risk factors, providing epidemiological support for heritable susceptibility. Complementary work from the UK Biobank has estimated the heritability of DFU at roughly 25-30%, confirming that genetics contribute meaningfully to the clinical picture.

The Genetic Landscape of Diabetic Foot Ulcer Susceptibility

The genetic architecture of DFU susceptibility is best understood through the lens of biological pathways that are critical to wound healing and tissue homeostasis. When a foot ulcer begins to form — typically from repetitive mechanical stress on an insensate foot — the normal healing cascade must function efficiently to re-epithelialize the wound. Any genetic perturbation that delays or derails this cascade can transform a trivial abrasion into a chronic, non-healing ulcer. The major domains where genetic variation exerts influence include angiogenesis and vascular function, extracellular matrix remodeling, inflammatory regulation, and nerve integrity.

Angiogenesis and Vascular Function: The VEGF Axis

Perhaps no single gene has been studied more extensively in the context of DFU susceptibility than Vascular Endothelial Growth Factor A (VEGFA). VEGF is the master regulator of angiogenesis, stimulating endothelial cell proliferation, migration, and tube formation to restore blood supply to injured tissue. In diabetic patients, VEGF expression is often dysregulated — paradoxically, it is elevated in the retina (contributing to proliferative retinopathy) but suppressed in ischemic tissues such as the foot. This tissue-specific discordance is partly genetically determined.

Multiple polymorphisms in the VEGFA promoter region have been associated with DFU risk. The most well-characterized is the -2578C/A (rs699947) single nucleotide polymorphism (SNP). The A allele has been linked to lower VEGF production under hypoxic conditions, leading to impaired collateral vessel formation and reduced perfusion to the distal extremities. A meta-analysis of seven studies found that carriers of the A allele had a 1.4-fold increased odds of developing DFU compared to CC homozygotes. Similarly, the -634G/C polymorphism (rs2010963) influences VEGF splicing efficiency and has been associated with delayed wound closure in clinical cohorts.

Beyond VEGFA itself, genes encoding VEGF receptors — particularly FLT1 (VEGFR-1) and KDR (VEGFR-2) — harbor variants that modulate response to VEGF signaling. Polymorphisms in HIF1A, the master transcriptional regulator of the hypoxia response that sits upstream of VEGF, also show significant associations. The HIF1A Pro582Ser variant (rs11549465) results in altered protein stability under normoxic conditions, blunting the normal hypoxic drive to angiogenesis. Patients carrying this variant demonstrate poorer wound oxygenation and higher rates of ulcer recurrence.

Extracellular Matrix and Collagen Metabolism

The structural integrity of skin and underlying connective tissue depends on proper collagen synthesis, crosslinking, and degradation. Genetic variants that disrupt these processes can render the plantar skin more susceptible to pressure-induced breakdown and less capable of generating the scaffold necessary for tissue repair.

Matrix Metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) are central regulators of wound matrix turnover. The MMP-9 -1562C/T polymorphism (rs3918242) has been extensively investigated. The T allele creates a transcription factor binding site that increases MMP-9 expression. In the setting of a diabetic wound, excessive MMP-9 activity degrades newly formed granulation tissue and impairs epithelial migration, converting an acute wound into a chronic one. A 2022 study of 412 diabetic patients found that T allele carriers had a 2.1-fold increased risk of ulceration and significantly longer healing times after standard therapy.

Collagen-related genes also feature prominently. COL1A1 and COL3A1 polymorphisms influence fiber diameter and crosslinking density. The COL1A1 Sp1 binding site polymorphism (rs1800012) is associated with altered collagen fibril architecture and lower tissue tensile strength in the skin. While initially studied in the context of osteoporosis and hernias, emerging evidence links this variant to increased susceptibility to foot ulceration, particularly in elderly diabetic patients with thin, fragile skin. ELN (elastin) and LOX (lysyl oxidase) gene variants further contribute to the mechanical properties of plantar soft tissue, with certain haplotypes correlating with reduced shock absorption capacity and higher peak plantar pressures during gait.

Inflammatory Signaling: The Double-Edged Sword

Wound healing requires a coordinated inflammatory response — enough to clear debris and pathogens, but not so vigorous that it causes collateral tissue damage. Genetic variation in inflammatory cytokines and their receptors can tip this balance toward chronic inflammation or impaired immune mobilization, both of which predispose to ulcer formation and delayed healing.

Tumor Necrosis Factor Alpha (TNFA) is a critical pro-inflammatory mediator. The TNFA -308G/A polymorphism (rs1800629), where the A allele confers higher transcriptional activity, has been consistently associated with DFU risk. In a prospective cohort of 850 diabetic patients followed for five years, AA homozygotes had a 2.4-fold increased hazard of developing a first foot ulcer compared to GG carriers, even after adjustment for smoking, HbA1c, and Charcot arthropathy. This association is thought to reflect an exaggerated inflammatory response to minor trauma that causes excessive tissue necrosis and delays wound resolution.

Interleukin-1 Beta (IL1B) and Interleukin-1 Receptor Antagonist (IL1RN) form a regulatory axis that determines the intensity and duration of local inflammation. A variable number tandem repeat (VNTR) polymorphism in IL1RN has been linked to altered IL-1 signaling balance. Carriers of the short allele (two repeats) display a more pro-inflammatory phenotype and show higher rates of ulcer recurrence in longitudinal studies. Conversely, polymorphisms in anti-inflammatory cytokines such as IL10 and TGFB1 that reduce their expression are also risk-conferring, illustrating the delicate equilibrium required for optimal healing.

A 2023 GWAS of over 12,000 individuals with diabetes identified a novel risk locus near the IL6R gene, encoding the interleukin-6 receptor. This locus is particularly interesting because the same allele that increases DFU risk also protects against rheumatoid arthritis, highlighting the tissue-specific and context-dependent nature of inflammatory genetic effects.

Neural and Neurotrophic Factors

Peripheral neuropathy is the single strongest clinical predictor of DFU, and genetic factors that influence nerve fiber density, axonal regeneration, and neurotrophic support modulate this risk. Nerve Growth Factor (NGF) and its receptor TrkA (NTRK1) play essential roles in maintaining small fiber integrity. Polymorphisms that reduce NGF expression or TrkA signaling have been associated with earlier onset and greater severity of diabetic neuropathy, indirectly increasing ulcer risk.

NAV2, a gene involved in neuronal growth cone guidance, was identified as a risk locus in a recent candidate gene study of South Asian diabetic populations. The risk allele correlates with reduced nerve conduction velocities in the sural and peroneal nerves, suggesting that genetic vulnerability extends to the structural integrity of peripheral nerves themselves. Additionally, genes encoding voltage-gated sodium channels such as SCN9A influence pain perception thresholds — patients with certain SCN9A variants experience diminished protective pain from repetitive trauma, allowing ulcers to develop without typical warning signals.

Genetic Predisposition and Risk Assessment in Clinical Practice

The accumulation of genetic association data has spurred interest in developing polygenic risk scores (PRS) for DFU susceptibility. A PRS aggregates the effects of multiple independent risk variants across the genome into a single quantitative measure. For DFU, the most comprehensive PRS to date incorporates approximately 45 SNPs spanning VEGF, MMP, cytokine, collagen, and neurotrophic pathways. Validation studies show that individuals in the highest PRS quintile have a 3.2-fold increased odds of DFU compared to the lowest quintile, and importantly, this risk is additive to traditional clinical risk factors.

Family history remains a practical and inexpensive genetic screening tool. Clinicians should ask diabetic patients about first-degree relatives (parents, siblings, children) with a history of foot ulcers or amputations. A positive family history warrants intensified foot surveillance, including more frequent podiatry referrals, custom orthotics, and patient education about signs of impending ulceration. While family history cannot pinpoint specific variants, it captures shared genetic and environmental factors that collectively increase risk.

Emerging Genetic Screening Technologies

Commercial genetic testing panels for DFU risk are beginning to appear, though their clinical utility remains under investigation. These panels typically genotype 10-20 candidate variants in VEGF, MMP-9, TNFA, and other well-validated loci. Results are reported as a "genetic risk score" stratified into low, moderate, or high risk. A positive test does not guarantee ulcer development, nor does a negative test confer complete protection — rather, it shifts the pre-test probability and informs the intensity of preventive interventions.

Challenges remain before widespread adoption is feasible. Most studies have been conducted in European-ancestry populations, and the generalizability of risk variants to African, East Asian, Hispanic, and South Asian populations is uncertain. The prevalence of certain risk alleles differs markedly across ethnic groups, and social determinants of health — including access to footwear, foot care education, and medical services — interact with genetic risk in ways that require further study. Moreover, the positive predictive value of current panels is modest, and there is a risk of false reassurance among patients who are told they have "low genetic risk" but who have strong clinical risk factors such as neuropathy or prior ulceration.

Despite these limitations, genetic risk assessment may prove most valuable in a specific clinical niche: the diabetic patient without classic risk factors who nonetheless develops an ulcer. In this scenario, a high PRS could identify the biologic basis of vulnerability and justify more aggressive preventive measures that would not otherwise be indicated by conventional risk stratification.

Gene-Environment Interactions and Epigenetic Modulation

Genetics do not operate in a vacuum. The same risk allele can have dramatically different effects depending on the patient's metabolic environment, lifestyle factors, and cumulative exposure to hyperglycemia. Understanding these gene-environment interactions is essential for translating genetic knowledge into actionable clinical strategies.

Consider the VEGFA -2578A variant described earlier. In a well-controlled diabetic patient with HbA1c under 7% and normal renal function, this allele may confer only a modest risk increase. However, in a patient with HbA1c above 9% and chronic kidney disease, the effect of the same variant is amplified — the poor metabolic environment further suppresses VEGF signaling, pushing the patient across the threshold from compensated healing to ulceration. This interaction has been confirmed in multiple cohorts and underscores that genetic risk is context-dependent.

Epigenetic Modifications: The Interface Between Genes and Environment

Epigenetic changes — including DNA methylation, histone modification, and microRNA regulation — are heritable alterations in gene expression that do not change the underlying DNA sequence. In diabetes, chronic hyperglycemia induces widespread epigenetic reprogramming that influences the same pathways governed by germline genetic variants. For instance, the MMP-9 promoter can become hypomethylated in hyperglycemic states, leading to sustained overexpression that mimics the effect of the -1562T risk allele. This creates a scenario where patients who do not carry the inherited risk variant can acquire a functionally similar epigenetic state, achieving equivalent risk through an acquired mechanism.

Similarly, microRNAs such as miR-21 and miR-146a, which regulate inflammatory and fibrotic pathways in wounds, are consistently dysregulated in diabetic foot tissue. MiR-146a normally suppresses inflammatory signaling by targeting IRAK1 and TRAF6, but its expression is reduced in diabetic wounds. Genetic variants in the miR-146a primary transcript (rs2910164) further modulate this suppression, creating a gene-epigenetic interaction that influences healing trajectory.

Importantly, epigenetic marks are potentially reversible. Therapeutic agents that inhibit DNA methyltransferases or histone deacetylases are being explored for diabetic wound healing in preclinical models. While these are not yet clinically available for DFU, the concept of pharmacologically resetting the epigenetic clock is an exciting frontier. Lifestyle interventions — particularly diet and exercise — also influence the epigenome, and some evidence suggests that stringent glycemic control early in diabetes can reverse certain maladaptive methylation patterns. This provides a mechanistic basis for the observation that intensive glucose management in the first few years after diagnosis reduces long-term risk of foot complications, even if control later deteriorates — a phenomenon known as metabolic memory.

Implications for Treatment and Prevention: The Era of Personalized Wound Care

The recognition that genetic susceptibility underlies DFU risk has practical implications that extend beyond risk prediction. It opens the door to genetically informed therapeutic strategies that target specific biological vulnerabilities in individual patients.

Tailored Prevention Strategies Based on Genetic Risk

Patients identified as having high genetic risk through family history or PRS should be enrolled in intensified surveillance programs. This includes quarterly foot examinations by a podiatrist, custom offloading insoles designed to redistribute plantar pressure, daily self-inspection with structured checklists, and immediate antibiotic therapy for any suspected infection. Telemedicine-based foot monitoring using smartphone photography — with or without artificial intelligence analysis — can provide cost-effective remote surveillance for high-risk patients who cannot attend frequent in-person visits.

Importantly, genetic risk information can motivate patients to adhere to preventive behaviors. Studies in cardiovascular prevention show that sharing genetic risk scores improves medication adherence and lifestyle modification, and early data suggest similar effects in diabetes foot care. Patients who learn they carry risk variants for impaired angiogenesis or collagen weakness may be more willing to wear prescribed offloading footwear, which has notoriously poor compliance rates in standard practice.

Gene-Targeted Therapeutic Approaches

For patients who carry VEGF risk variants with reduced angiogenic capacity, topical or injected VEGF-A therapy has been tested in clinical trials. A pilot randomized controlled trial of topical recombinant human VEGF gel in patients with chronic DFUs showed a non-significant trend toward increased complete healing at 12 weeks compared to placebo gel, with benefit concentrated in patients with low baseline VEGF levels. While this did not meet statistical significance in the small sample, subgroup analysis suggested that patients with specific VEGF genotypes had a more robust response. Larger trials stratified by genotype are now in development.

For patients with excessive MMP-9 activity — either from inherited variants or epigenetic upregulation — MMP inhibitors have been explored. Doxycycline, at sub-antimicrobial doses, functions as a broad-spectrum MMP inhibitor. Clinical studies have demonstrated improved healing rates in DFU patients treated with topical doxycycline gel in combination with standard care, particularly in those with elevated wound MMP-9 levels. Genotyping could identify candidates most likely to benefit while sparing patients with low MMP-9 from unnecessary treatment.

For patients with high genetic inflammatory tone (e.g., TNFA -308 A carriers), anti-TNF therapies could theoretically be repurposed for DFU healing. Systemic TNF inhibitors such as adalimumab carry safety concerns in diabetic patients with infection risk, but topical or localized delivery might mitigate these risks. Preclinical studies in diabetic mice show that topical etanercept accelerates wound closure and reduces inflammatory infiltrate, and early-phase human trials are ongoing.

Integrating Genetic Information into Standard Clinical Pathways

For genetics to meaningfully impact DFU outcomes, testing must be integrated into existing care frameworks rather than siloed in specialized clinics. The logical point of integration is the annual diabetes review, where foot examination, neuropathy assessment, and risk stratification are already standard. Adding a genetic component — either through family history collection or, where accessible, a point-of-care genotyping panel — would provide a more complete risk picture without requiring major changes to clinical workflow.

Electronic health record (EHR) systems can be programmed to flag patients with high genetic risk and trigger automated referrals for podiatry or vascular assessment. Clinical decision support tools could incorporate PRS data alongside HbA1c, monofilament testing results, and ankle-brachial index to generate a composite risk score that drives personalized follow-up intervals. As direct-to-consumer genetic testing becomes more common, patients may present to their diabetes care providers with their own genetic data, and clinicians must be prepared to interpret and act on this information appropriately.

The American Diabetes Association's 2024 Standards of Care now recognize family history of foot ulcers as a major risk factor, and many experts anticipate that formal genetic risk testing will be incorporated into future guidelines as evidence matures.

Future Directions and Unresolved Questions

The field of DFU genetics is advancing rapidly, but significant gaps remain. Most genetic association studies have been relatively small, underpowered, and focused on candidate genes rather than unbiased genome-wide approaches. Large-scale GWAS with diverse ancestry representation are urgently needed to identify novel loci and validate existing findings across populations. The DIAMANTE consortium, which brings together GWAS data from over 200,000 diabetic individuals, has begun to address this gap, and DFU-specific analyses are expected in the coming years.

Pharmacogenomics — the study of how genetic variation affects drug response — holds particular promise for DFU treatment. One gene of interest is NOS3, which encodes endothelial nitric oxide synthase. Polymorphisms in NOS3 influence nitric oxide production, and patients with certain haplotypes show differential healing responses to topical nitric oxide donors such as nitrate-based dressings. Similarly, variants in PDGFRB may predict response to platelet-derived growth factor (becaplermin) therapy.

The role of the skin microbiome in DFU susceptibility is an emerging area that intersects with host genetics. Variants in genes encoding antimicrobial peptides such as DEFB4 (beta-defensin-2) and CAMP (cathelicidin) influence the composition of the cutaneous microbiome and the ability to resist colonization by pathogens like Staphylococcus aureus and Pseudomonas aeruginosa. Combining genetic analysis with microbiome profiling could identify patients at risk for biofilm-associated healing failure and guide selective antimicrobial therapy.

Finally, the study of the genetics of Charcot neuroarthropathy — a destructive joint condition that often precedes or accompanies DFU — remains in its infancy. Shared genetic pathways between Charcot and ulceration suggest that a unified genetic risk score for foot complications may ultimately emerge. Genes involved in RANKL/RANK/OPG signaling, which regulates osteoclast activity, are promising candidates and may have common variants that predispose to both bone and soft tissue complications in the diabetic foot.

Conclusion

Diabetic foot ulcers are not a stochastic complication of diabetes but rather a condition with well-defined genetic underpinnings that interact with environmental and metabolic factors. Variants in genes controlling angiogenesis (VEGFA, HIF1A), extracellular matrix remodeling (MMP-9, COL1A1), inflammatory signaling (TNFA, IL1RN), and neurotrophic support (NGF, NAV2) collectively shape an individual's susceptibility. Family history provides a clinically accessible proxy for this genetic burden, and emerging polygenic risk scores offer the potential for more precise stratification.

Recognizing the genetic contribution to DFU shifts the clinical paradigm from reactive treatment of established wounds to proactive, genetically informed prevention. Patients at high genetic risk merit intensified surveillance, aggressive risk factor modification, and early referral for specialized care. As gene-targeted therapies and pharmacogenomic approaches mature, treatment itself may become personalized, with wound care selected based on the patient's specific genetic vulnerability — be it impaired angiogenesis, excessive matrix degradation, or dysregulated inflammation.

The convergence of genomic science, digital health tools, and a deeper understanding of wound healing biology promises to reduce the incidence and severity of diabetic foot ulcers in the coming decade. Clinicians who integrate genetic thinking into their daily practice will be better equipped to identify the highest-risk patients, deploy preventive resources efficiently, and ultimately spare their patients the devastating consequences of amputation and loss of mobility. The future of diabetic foot care is personalized, and genetics is a cornerstone of that future.